Alkermes plc. ($ALKS)
Filing Information
| Accession Number | 0001520262-26-000009 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 3, 2026 |
| Document Date | Feb 2, 2026 |
| Document | View SEC Filing |
Transactions
4
Total Shares
19,000
Total Value
$402,084.50
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Feb 2, 2026 | Exercise/Conversion | 5,000 | $19.34 | $96,700.00 | 66,740 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Feb 2, 2026 | Sale | 5,000 | $34.24 | $171,224.50 | 61,740 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Ordinary Shares | โ | Feb 2, 2026 | Sale | 4,000 | $33.54 | $134,160.00 | 57,740 | Direct | โ | View Details | |
EVP R&D, Chief Medical Officer | Employee Stock Option (Right to Buy) | Derivative | Feb 2, 2026 | Exercise/Conversion | 5,000 | $0.00 | $0.00 | 26,356 | Direct | โ | View Details |